SCHEMBL6520210

SCHEMBL6520210

O=C(O)Cc1cc(C(F)(F)F)c(Oc2ccc3[nH]cc(Cc4ccccc4)c3c2)c(C(F)(F)F)c1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
THRA P10827 10/20 0.68
THRB P10828 10/20 0.68
KDM4E B2RXH2 1/20 0.47
LTA4H P09960 2/20 0.42
PLA2G2A P14555 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
ICMT O60725 1/20 0.42
TSHR P16473 1/20 0.42
SNCA P37840 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
GPR84 Q9NQS5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6512487 0.93 THRB (0.60) THRATHRBKDM4ESNCA
SCHEMBL6515914 0.93 THRA (0.62) THRATHRBKDM4ELTA4HPLA2G2A
SCHEMBL6520865 0.93 THRB (0.60) THRATHRBKDM4E
SCHEMBL6517048 0.92 THRA (0.66) THRATHRBKDM4ETSHRSNCA
SCHEMBL6520134 0.91 THRA (0.65) THRATHRBKDM4ETSHRSNCA
SCHEMBL6511409 0.87 THRB (0.59) THRATHRBKDM4ESNCA
SCHEMBL6515972 0.86 THRB (0.59) THRATHRBKDM4ETSHR
SCHEMBL6516405 0.86 THRA (0.64) THRATHRBKDM4ETSHRPPARG
SCHEMBL6515549 0.86 THRB (0.59) THRATHRBKDM4ETSHRSNCA
SCHEMBL6860169 0.86 THRA (0.71) THRATHRBKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 THRA 2460/4885THRB 1772/4885KDM4E 1199/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP THRA 1917/4885THRB 1835/4885KDM4E 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.